Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

The efficacy of empagliflozin for non-alcoholic fatty liver disease remains controversial. This meta-analysis aims to explore the influence of empagliflozin versus placebo on the treatment of non-alcoholic fatty liver disease and we have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane l...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xue, Zhang, Huaping, Wang, Xin, Yang, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Makerere Medical School 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993318/
https://www.ncbi.nlm.nih.gov/pubmed/36910362
http://dx.doi.org/10.4314/ahs.v22i3.42

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993318/
https://www.ncbi.nlm.nih.gov/pubmed/36910362
http://dx.doi.org/10.4314/ahs.v22i3.42

Ejemplares similares